Skip to main content
SpringerLink
Log in
Book cover

Metabolic Control pp 437–459Cite as

Current and Emerging Treatment Options in Diabetes Care

  • Chapter

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 233))

Abstract

Diabetes constitutes an increasing threat to human health, particularly in newly industrialized and densely populated countries. Type 1 and type 2 diabetes arise from different etiologies but lead to similar metabolic derangements constituted by an absolute or relative lack of insulin that results in elevated plasma glucose. In the last three decades, a set of new medicines built upon a deeper understanding of physiology and diabetic pathology have emerged to enhance the clinical management of the disease and related disorders. Recent insights into insulin-dependent and insulin-independent molecular events have accelerated the generation of a series of novel medicinal agents, which hold the promise for further advances in the management of diabetes. In this chapter, we provide a historical context for what has been accomplished to provide perspective for future research and novel emerging treatment options.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Adams AC, Yang C, Coskun T, Cheng CC, Gimeno RE, Luo Y, Kharitonenkov A (2012a) The breadth of FGF21’s metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab 2:31–37

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Adams TD, Davidson LE, Litwin SE, Kolotkin RL, LaMonte MJ, Pendleton RC, Strong MB, Vinik R, Wanner NA, Hopkins PN, Gress RE, Walker JM, Cloward TV, Nuttall RT, Hammoud A, Greenwood JL, Crosby RD, McKinlay R, Simper SC, Smith SC, Hunt SC (2012b) Health benefits of gastric bypass surgery after 6 years. JAMA 308:1122–1131

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Andersen B, Beck-Nielsen H, Hojlund K (2011) Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers. Clin Endocrinol 75:514–519

    Article  CAS  Google Scholar 

  • Aroda VR, Ratner R (2011) The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev 27:528–542

    Article  CAS  PubMed  Google Scholar 

  • Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157

    Article  CAS  PubMed  Google Scholar 

  • Bailey T (2013) Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. Am J Med 126:S10–S20

    Article  PubMed  Google Scholar 

  • Bailey CJ, Turner RC (1996) Metformin. N Engl J Med 334:574–579

    Article  CAS  PubMed  Google Scholar 

  • Balena R, Hensley IE, Miller S, Barnett AH (2013) Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 15:485–502

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barnett AH (2013) Complementing insulin therapy to achieve glycemic control. Adv Ther 30:557–576

    Article  PubMed  Google Scholar 

  • Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S (2011) Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 154:602–613

    Article  PubMed  PubMed Central  Google Scholar 

  • Berthoud HR, Shin AC, Zheng H (2011) Obesity surgery and gut-brain communication. Physiol Behav 105:106–119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Blickle JF (2006) Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab 32:113–120

    Article  CAS  PubMed  Google Scholar 

  • Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293–1300

    Article  CAS  PubMed  Google Scholar 

  • Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386–399

    Article  PubMed  Google Scholar 

  • Bonora E, Tuomilehto J (2011) The pros and cons of diagnosing diabetes with A1C. Diabetes Care 34(Suppl 2):S184–S190

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Booth SL, Centi A, Smith SR, Gundberg C (2013) The role of osteocalcin in human glucose metabolism: marker or mediator? Nat Rev Endocrinol 9:43–55

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bouwens L, Houbracken I, Mfopou JK (2013) The use of stem cells for pancreatic regeneration in diabetes mellitus. Nat Rev Endocrinol 9:598–606

    Article  CAS  PubMed  Google Scholar 

  • Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258

    Article  PubMed  Google Scholar 

  • Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I (2009) Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122(248–256):e5

    PubMed  Google Scholar 

  • Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang D, Chang JK, Rizza RA (1990) Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 39:752–756

    Article  CAS  PubMed  Google Scholar 

  • Cefalu WT (2007) Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents. Clin Pharmacol Ther 81:636–649

    Article  CAS  PubMed  Google Scholar 

  • Cegla J, Troke RC, Jones B, Tharakan G, Kenkre J, McCullough KA, Lim CT, Parvizi N, Hussein M, Chambers ES, Minnion J, Cuenco J, Ghatei MA, Meeran K, Tan TM, Bloom SR (2014) Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63:3711–3720

    Article  CAS  PubMed  Google Scholar 

  • Chabenne J, Chabenne MD, Zhao Y, Levy J, Smiley D, Gelfanov V, Dimarchi R (2014) A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia. Mol Metab 3:293–300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chambers AP, Kirchner H, Wilson-Perez HE, Willency JA, Hale JE, Gaylinn BD, Thorner MO, Pfluger PT, Gutierrez JA, Tschop MH, Sandoval DA, Seeley RJ (2013) The effects of vertical sleeve gastrectomy in rodents are ghrelin independent. Gastroenterology 144(50–52):e5

    PubMed  Google Scholar 

  • Clemmensen C, Chabenne J, Finan B, Sullivan L, Fischer K, Kuchler D, Sehrer L, Ograjsek T, Hofmann SM, Schriever SC, Pfluger PT, Pinkstaff J, Tschop MH, Dimarchi R, Muller TD (2014) GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 63:1422–1427

    Article  CAS  PubMed  Google Scholar 

  • Cummings DE, Overduin J, Shannon MH, Foster-Schubert KE, Conference ABSC (2005) Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Surg Obes Relat Dis 1:358–368

    Article  PubMed  Google Scholar 

  • Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777

    Article  CAS  PubMed  Google Scholar 

  • D’Alessio D (2011) The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab 13(Suppl. 1):126–132

    Google Scholar 

  • Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N, Holland J, Hembree J, Abplanalp W, Grant E, Ruehl J, Wilson H, Kirchner H, Lockie SH, Hofmann S, Woods SC, Nogueiras R, Pfluger PT, Perez-Tilve D, DiMarchi R, Tschop MH (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5:749–757

    Article  CAS  PubMed  Google Scholar 

  • Defronzo RA, Mehta RJ, Schnure JJ (2013) Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract 41:132–147

    Article  Google Scholar 

  • Derosa G, Sibilla S (2007) Optimizing combination treatment in the management of type 2 diabetes. Vasc Health Risk Manag 3:665–671

    CAS  PubMed  PubMed Central  Google Scholar 

  • Dieterle CD, Arbogast H, Illner WD, Schmauss S, Landgraf R (2007) Metabolic follow-up after long-term pancreas graft survival. Eur J Endocrinol 156:603–610

    Article  CAS  PubMed  Google Scholar 

  • Dupre J, Ross SA, Watson D, Brown JC (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37:826–828

    Article  CAS  PubMed  Google Scholar 

  • Elkinson S, Scott LJ (2013) Canagliflozin: first global approval. Drugs 73:979–988

    Article  CAS  PubMed  Google Scholar 

  • Elrick H, Stimmler L, Hlad CJ Jr, Arai Y (1964) Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metabol 24:1076–1082

    Article  CAS  Google Scholar 

  • Falken Y, Hellstrom PM, Holst JJ, Naslund E (2011) Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 96:2227–2235

    Article  CAS  PubMed  Google Scholar 

  • Fehmann HC, Goke R, Goke B (1995) Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 16:390–410

    Article  CAS  PubMed  Google Scholar 

  • Fernandez-Real JM, Broch M, Ricart W, Casamitjana R, Gutierrez C, Vendrell J, Richart C (1998) Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 47:1757–1762

    Article  CAS  PubMed  Google Scholar 

  • Ferrannini E, Solini A (2012) SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8:495–502

    Article  CAS  PubMed  Google Scholar 

  • Finan B, Yang B, Ottaway N, Stemmer K, Muller TD, Yi CX, Habegger K, Schriever SC, Garcia-Caceres C, Kabra DG, Hembree J, Holland J, Raver C, Seeley RJ, Hans W, Irmler M, Beckers J, de Angelis MH, Tiano JP, Mauvais-Jarvis F, Perez-Tilve D, Pfluger P, Zhang L, Gelfanov V, DiMarchi RD, Tschop MH (2012) Targeted estrogen delivery reverses the metabolic syndrome. Nat Med 18:1847–1856

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruemmer D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gidda J, Vignati L, Zhang L, Hauptman JB, Lau M, Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde-Knape K, Konkar A, DiMarchi RD, Tschop MH (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5:209ra151

    Google Scholar 

  • Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, Campbell JE, Sandoval D, Seeley RJ, Bleicher K, Uhles S, Riboulet W, Funk J, Hertel C, Belli S, Sebokova E, Conde-Knape K, Konkar A, Drucker DJ, Gelfanov V, Pfluger PT, Muller TD, Perez-Tilve D, DiMarchi RD, Tschop MH (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21:27–36

    Article  CAS  PubMed  Google Scholar 

  • Foley JE, Jordan J (2010) Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag 6:541–548

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fonseca V (2003) Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 115(Suppl 8A):42S–48S

    Article  CAS  PubMed  Google Scholar 

  • Fonseca VA, Haggar MA (2014) Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment. Nat Rev Endocrinol 10:276–281

    Article  CAS  PubMed  Google Scholar 

  • Fonseca VA, Handelsman Y, Staels B (2010) Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab 12:384–392

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fuchtenbusch M, Standl E, Schatz H (2000) Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Experimental and clinical endocrinology & diabetes. J German Soc Endocrinol German Diabetes Assoc 108:151–163

    Google Scholar 

  • Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Dore J, Henegar C, Rizkalla S, Clement K (2010) Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59:3049–3057

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, Moller DE (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18:333–340

    Article  CAS  PubMed  Google Scholar 

  • Galman C, Lundasen T, Kharitonenkov A, Bina HA, Eriksson M, Hafstrom I, Dahlin M, Amark P, Angelin B, Rudling M (2008) The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 8:169–174

    Article  PubMed  CAS  Google Scholar 

  • Garg SK (2010) The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes–a comprehensive review. Diabetes Technol Ther 12:11–24

    Article  CAS  PubMed  Google Scholar 

  • Garg A, Grundy SM (1994) Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 121:416–422

    Article  CAS  PubMed  Google Scholar 

  • Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH (2012) Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 95:297–308

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gerich JE (1993) Control of glycaemia. Bailliere Clin Endocrinol Metab 7:551–586

    Article  CAS  Google Scholar 

  • German JP, Thaler JP, Wisse BE, Oh IS, Sarruf DA, Matsen ME, Fischer JD, Taborsky GJ Jr, Schwartz MW, Morton GJ (2011) Leptin activates a novel CNS mechanism for insulin-independent normalization of severe diabetic hyperglycemia. Endocrinology 152:394–404

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gruessner AC, Gruessner RW (2012) Pancreas transplant outcomes for United States and non United States cases as reported to the United Network for Organ Sharing and the International Pancreas Transplant Registry as of December 2011. Clin Transpl 23–40

    Google Scholar 

  • Gruessner RW, Gruessner AC (2013) The current state of pancreas transplantation. Nat Rev Endocrinol 9:555–562

    Article  CAS  PubMed  Google Scholar 

  • Gruessner AC, Sutherland DE (2005) Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transpl 19:433–455

    Article  Google Scholar 

  • Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103:137–149

    Article  CAS  PubMed  Google Scholar 

  • Habegger KM, Stemmer K, Cheng C, Muller TD, Heppner KM, Ottaway N, Holland J, Hembree JL, Smiley D, Gelfanov V, Krishna R, Arafat AM, Konkar A, Belli S, Kapps M, Woods SC, Hofmann SM, D'Alessio D, Pfluger PT, Perez-Tilve D, Seeley RJ, Konishi M, Itoh N, Kharitonenkov A, Spranger J, DiMarchi RD, Tschop MH (2013) Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62:1453–1463

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hadvary P, Lengsfeld H, Wolfer H (1988) Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 256:357–361

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Handelsman Y (2011) Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care 34(Suppl 2):S244–S250

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hauner H (2002) The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18(Suppl 2):S10–S15

    Article  CAS  PubMed  Google Scholar 

  • Hernandez AV, Usmani A, Rajamanickam A, Moheet A (2011) Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 11:115–128

    Article  CAS  PubMed  Google Scholar 

  • Hirsch IB (2005) Insulin analogues. N Engl J Med 352:174–183

    Article  CAS  PubMed  Google Scholar 

  • Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J (1998) Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21:1288–1294

    Article  CAS  PubMed  Google Scholar 

  • Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K, Group CO-DS (2013) Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes care 36:4022–4029

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y (2001) Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126–1133

    Article  CAS  PubMed  Google Scholar 

  • Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P (2009) Bile acids as regulatory molecules. J Lipid Res 50:1509–1520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • IDF (2014) IDF Diabetes Atlas update poster, 6th edn. International Diabetes Federation, Brussels

    Google Scholar 

  • Inzucchi SE, McGuire DK (2008) New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation 117:574–584

    Article  PubMed  Google Scholar 

  • Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46:3–19

    Article  CAS  PubMed  Google Scholar 

  • Kahn BB, Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106:473–481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846

    Article  CAS  PubMed  Google Scholar 

  • Kahn SE, Suvag S, Wright LA, Utzschneider KM (2012) Interactions between genetic background, insulin resistance and beta-cell function. Diabetes Obes Metab 14(Suppl. 3):46–56

    Google Scholar 

  • Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR (2012) The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 62:1916–1927

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK (2008) Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 247:401–407

    Article  PubMed  Google Scholar 

  • Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC (1967) Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 61:827–837

    CAS  PubMed  Google Scholar 

  • Kharitonenkov A, Adams AC (2014) Inventing new medicines: the FGF21 story. Mol Metab 3:221–229

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627–1635

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kievit P, Halem H, Marks DL, Dong JZ, Glavas MM, Sinnayah P, Pranger L, Cowley MA, Grove KL, Culler MD (2013) Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 62:490–497

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim GW, Lin JE, Blomain ES, Waldman SA (2014) Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther 95:53–66

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kleinridders A, Ferris HA, Cai W, Kahn CR (2014) Insulin action in brain regulates systemic metabolism and brain function. Diabetes 63:2232–2243

    Article  PubMed  PubMed Central  Google Scholar 

  • Knip M, Veijola R, Virtanen SM, Hyoty H, Vaarala O, Akerblom HK (2005) Environmental triggers and determinants of type 1 diabetes. Diabetes 54(Suppl 2):S125–S136

    Article  CAS  PubMed  Google Scholar 

  • Kruger DF, Gloster MA (2004) Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. Drugs 64:1419–1432

    Article  CAS  PubMed  Google Scholar 

  • Laeger T, Henagan TM, Albarado DC, Redman LM, Bray GA, Noland RC, Munzberg H, Hutson SM, Gettys TW, Schwartz MW, Morrison CD (2014) FGF21 is an endocrine signal of protein restriction. J Clin Invest 124:3913–3922

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lebovitz HE (1997) alpha-Glucosidase inhibitors. Endocrinol Metab Clin N Am 26:539–551

    Article  CAS  Google Scholar 

  • Lee P, Linderman J, Smith S, Brychta RJ, Perron R, Idelson C, Werner CD, Chen KY, Celi FS (2013) Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans? Osteoporos Int 24:3053–3057

    Article  CAS  PubMed  Google Scholar 

  • Liu SC, Tu YK, Chien MN, Chien KL (2012) Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 14:810–820

    Article  CAS  PubMed  Google Scholar 

  • Lutz TA, Bueter M (2014) The physiology underlying Roux-en-Y gastric bypass: a status report. Am J Physiol Regul Integr Comp Physiol 307:R1275–R1291

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Makimattila S, Nikkila K, Yki-Jarvinen H (1999) Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 42:406–412

    Article  CAS  PubMed  Google Scholar 

  • Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR (1992) Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925–929

    Article  CAS  PubMed  Google Scholar 

  • McIntyre N, Holdsworth CD, Turner DS (1964) New Interpretation of Oral Glucose Tolerance. Lancet 2:20–21

    Article  CAS  PubMed  Google Scholar 

  • Melander A (2004) Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview. Diabetes 53(Suppl 3):S151–S155

    Article  CAS  PubMed  Google Scholar 

  • Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, Foreyt J, Aronne L, Klein S (2002) Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 25:1123–1128

    Article  CAS  PubMed  Google Scholar 

  • Mittendorfer B, Horowitz JF, DePaoli AM, McCamish MA, Patterson BW, Klein S (2011) Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes. Diabetes 60:1474–1477

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mogensen UM, Andersson C, Fosbol EL, Schramm TK, Vaag A, Scheller NM, Torp-Pedersen C, Gislason G, Kober L (2015) Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study. Diabetologia 58:50–58

    Article  CAS  PubMed  Google Scholar 

  • Moon HS, Matarese G, Brennan AM, Chamberland JP, Liu X, Fiorenza CG, Mylvaganam GH, Abanni L, Carbone F, Williams CJ, De Paoli AM, Schneider BE, Mantzoros CS (2011) Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes 60:1647–1656

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Moore CX, Cooper GJ (1991) Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem Biophys Res Commun 179:1–9

    Article  CAS  PubMed  Google Scholar 

  • Morrow L, Hompesch M, Guthrie H, Chang D, Chatterjee DJ (2011) Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab 13:75–80

    Article  CAS  PubMed  Google Scholar 

  • Morton GJ, Schwartz MW (2011) Leptin and the central nervous system control of glucose metabolism. Physiol Rev 91:389–411

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Muller TD, Sullivan LM, Habegger K, Yi CX, Kabra D, Grant E, Ottaway N, Krishna R, Holland J, Hembree J, Perez-Tilve D, Pfluger PT, DeGuzman MJ, Siladi ME, Kraynov VS, Axelrod DW, DiMarchi R, Pinkstaff JK, Tschop MH (2012) Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci 18:383–393

    Article  PubMed  CAS  Google Scholar 

  • Myers MG, Cowley MA, Munzberg H (2008) Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 70:537–556

    Article  CAS  PubMed  Google Scholar 

  • Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes A, European Association for Study of D (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabet Care 32:193–203

    Article  CAS  Google Scholar 

  • Nauck MA (2014) Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 8:1335–1380

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Neschen S, Scheerer M, Seelig A, Huypens P, Schultheiss J, Wu M, Wurst W, Rathkolb B, Suhre K, Wolf E, Beckers J, Hrabe de Angelis M (2015) Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice. Diabetes 64:284–290

    Article  CAS  PubMed  Google Scholar 

  • Obici S, Feng Z, Tan J, Liu L, Karkanias G, Rossetti L (2001) Central melanocortin receptors regulate insulin action. J Clin Invest 108:1079–1085

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Raether B, Anderson CM, Shanahan WR (2012) Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 20:1426–1436

    Article  PubMed  CAS  Google Scholar 

  • Park JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, Gorden P (2008) Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. J Clin Endocrinol Metab 93:26–31

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, SinhaRoy R (2009) Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58:2258–2266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Proks P, Reimann F, Green N, Gribble F, Ashcroft F (2002) Sulfonylurea stimulation of insulin secretion. Diabetes 51(Suppl 3):S368–S376

    Article  CAS  PubMed  Google Scholar 

  • Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG (2004) Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabetic Med 21:1204–1212

    Article  CAS  PubMed  Google Scholar 

  • Rojas JM, Schwartz MW (2014) Control of hepatic glucose metabolism by islet and brain. Diabetes Obes Metab 16(Suppl. 1):33-40

    Google Scholar 

  • Roth JD (2013) Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology. Curr Opin Endocrinol Diabetes Obes 20:8–13

    Article  CAS  PubMed  Google Scholar 

  • Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG, Baron AD (2008) Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 105:7257–7262

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rueda-Clausen CF, Padwal RS, Sharma AM (2013) New pharmacological approaches for obesity management. Nat Rev Endocrinol 9:467–478

    Article  CAS  PubMed  Google Scholar 

  • Ryan GJ, Jobe LJ, Martin R (2005) Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 27:1500–1512

    Article  CAS  PubMed  Google Scholar 

  • Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R, Wilson-Perez HE, Sandoval DA, Kohli R, Backhed F, Seeley RJ (2014) FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509:183–188

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sadry SA, Drucker DJ (2013) Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol 9:425–433

    Article  CAS  PubMed  Google Scholar 

  • Saltiel AR, Olefsky JM (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661–1669

    Article  CAS  PubMed  Google Scholar 

  • Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE, Kashyap SR, Investigators S (2014) Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes. N Engl J Med 370:2002–2013

    Article  PubMed  CAS  Google Scholar 

  • Scheen AJ, Van Gaal LF (2014) Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2:911–922

    Article  CAS  PubMed  Google Scholar 

  • Schmidt WE, Siegel EG, Creutzfeldt W (1985) Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28:704–707

    Article  CAS  PubMed  Google Scholar 

  • Schwartz MW, Seeley RJ, Tschop MH, Woods SC, Morton GJ, Myers MG, D'Alessio D (2013) Cooperation between brain and islet in glucose homeostasis and diabetes. Nature 503:59–66

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schwenk RW, Baumeier C, Finan B, Kluth O, Brauer C, Joost HG, DiMarchi RD, Tschop MH, Schurmann A (2014) GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice. Diabetologia 58:604–614

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Scully T (2012) Diabetes in numbers. Nature 485:S2–S3

    Article  CAS  PubMed  Google Scholar 

  • Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA (2005) Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metab Clin Exp 54:24–32

    Article  CAS  PubMed  Google Scholar 

  • Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR, Behavioral M, Lorcaserin for O, Obesity Management Study G (2010) Multicenter, placebo-controlled trial of lorcaserin for weight management. New Engl J Med 363:245–256

    Article  CAS  PubMed  Google Scholar 

  • Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund Pedersen B (2000) Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529(Pt 1):237–242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tao YX (2010) The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev 31:506–543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, Hawkins M (2004) Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53:1621–1629

    Article  CAS  PubMed  Google Scholar 

  • Unger RH, Cherrington AD (2012) Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 122:4–12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • van Belle TL, Coppieters KT, von Herrath MG (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91:79–118

    Article  PubMed  CAS  Google Scholar 

  • van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C (2005) Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 28:154–163

    Article  PubMed  Google Scholar 

  • Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F (2012) Cellular and molecular mechanisms of metformin: an overview. Clin Sci 122:253–270

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vora J (2013) Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care 36(Suppl 2):S226–S232

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, Goetz R, Mohammadi M, Gerard RD, Dechow PC, Mangelsdorf DJ, Kliewer SA, Wan Y (2012) Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A 109:3143–3148

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Weir GC, Bonner-Weir S (2004) Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53(Suppl 3):S16–S21

    Article  CAS  PubMed  Google Scholar 

  • Weyer C, Maggs DG, Young AA, Kolterman OG (2001) Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 7:1353–1373

    Article  CAS  PubMed  Google Scholar 

  • Wilson-Perez HE, Chambers AP, Ryan KK, Li B, Sandoval DA, Stoffers D, Drucker DJ, Perez-Tilve D, Seeley RJ (2013) Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency. Diabetes 62:2380–2385

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wu Q, Wang L, Yu H, Wang J, Chen Z (2011) Organization of glucose-responsive systems and their properties. Chem Rev 111:7855–7875

    Article  CAS  PubMed  Google Scholar 

  • Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD (2002) Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25:2133–2140

    Article  CAS  PubMed  Google Scholar 

  • Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Diabetes and Obesity and Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany

    Christoffer Clemmensen, Timo D. Müller, Brian Finan & Matthias H. Tschöp

  2. Division of Metabolic Diseases, Department of Medicine, Technische Universität München, Munich, Germany

    Christoffer Clemmensen, Timo D. Müller, Brian Finan & Matthias H. Tschöp

  3. Department of Chemistry, Indiana University, Bloomington, IN, USA

    Richard DiMarchi

Authors
  1. Christoffer Clemmensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timo D. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brian Finan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matthias H. Tschöp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Richard DiMarchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias H. Tschöp .

Editor information

Editors and Affiliations

  1. Helmholtz Center Munich, and Heidelberg University Hospital, Professor and Director, Institute for Diabetes and Cancer IDC, and Joint Heidelberg-IDC Translational Diabetes Program, Neuherberg, Germany

    Stephan Herzig

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Clemmensen, C., Müller, T.D., Finan, B., Tschöp, M.H., DiMarchi, R. (2015). Current and Emerging Treatment Options in Diabetes Care. In: Herzig, S. (eds) Metabolic Control. Handbook of Experimental Pharmacology, vol 233. Springer, Cham. https://doi.org/10.1007/164_2015_7

Download citation

Publish with us

Policies and ethics

Search

Navigation